CLINICAL TRIALS PROFILE FOR MAPROTILINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for MAPROTILINE HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00108550 ↗ | Chronic Low Back Pain Research Project | Completed | US Department of Veterans Affairs | Phase 2 | 2004-10-01 | The purpose of this study is to determine whether gabapentin is efficacious as an analgesic for chronic low back pain. |
| NCT00108550 ↗ | Chronic Low Back Pain Research Project | Completed | VA Office of Research and Development | Phase 2 | 2004-10-01 | The purpose of this study is to determine whether gabapentin is efficacious as an analgesic for chronic low back pain. |
| NCT02374567 ↗ | Pharmacovigilance in Gerontopsychiatric Patients | Terminated | Hannover Medical School | Phase 3 | 2015-01-01 | The purpose of this multicenter-study is to investigate safety of psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric inpatients. Elderly people are at higher risk for developing side effects under pharmacological treatment due to an altered metabolic situation, higher comorbidity rates and often polypharmacy. Furthermore gerontopsychiatric patients can often not articulate their symptoms clearly, for example due to pronounced cognitive impairment. The aim of the study is to gain valid data of possible adverse drug reaction rates, their potential risk factors and outcome, as well as medical prescription practises. To assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the five participating study sites. At Baseline demographic data, previous and present disorders, use of drugs, previous and present medication, quality of life, cognitive function, physical examination results, laboratory results and ECG will be assessed. Afterwards patients are visited weekly and screened for possible adverse drug reactions. All adverse drug reactions will be coded in the MedDRA-system. In case of a possible serious adverse drug reaction serum levels of all psychotropic substances applicated will be assessed. Drug combinations will be analysed using an established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible adverse drug reactions are documented continually. 2 weeks after discharge from the ward, patients will be contacted by phone to assess catamnestic data. |
| NCT04200066 ↗ | A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma | Not yet recruiting | University of Rochester | Phase 1 | 2021-05-01 | The main purpose of this study is to find out the highest possible dose of maprotiline that can be given safely in combination with temozolomide and tamoxifen. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MAPROTILINE HYDROCHLORIDE
Condition Name
Clinical Trial Locations for MAPROTILINE HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for MAPROTILINE HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for MAPROTILINE HYDROCHLORIDE
Sponsor Name
